20th Conference on Retroviruses and Opportunistic Infections Atlanta GA March 3

Conference Reports for NATAP


20th Conference on Retroviruses and Opportunistic Infections Atlanta GA March 3 - 6, 2013

	CROI 2013 Adult Neurology Presentation and Abstracts Written for NATAP by Kevin R. Robertson, Ph.D.1, Charles Upton2 contributions by Jules Levin - (06/09/13) Clinical Pharmacology at CROI 2013 - Courtney V. Fletcher, Pharm.D. Dean and Professor College of Pharmacy University of Nebraska Medical Center 986000 Nebraska Medical Center Omaha, NE 68198 - (04/04/13) Update from 20th CROI: Bones, Vitamin D, Frailty - Todd T. Brown, MD, PhD Association Professor of Medicine and Epidemiology Division of Endocrinology and Metabolism Johns Hopkins University - (04/01/13) Summary from CROI 2013 for Hepatitis Co-infection HCV direct acting antivirals (DAAs) in HIV/HCV coinfection: More drugs on their way. What are the implications? - Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany - (03/29/13) The Kidney at CROI 2013 - Christina M. Wyatt, MD Assistant Professor, Medicine/ Nephrology Mount Sinai School of Medicine New York, NY - (03/21/13) Complications of HIV and its treatment, Impressions from the 20th CROI - Pablo Tebas, MD University of Pennsylvania - (03/20/13) CROI REPORT: New Drugs for HIV Treatment and other random thoughts - Joseph Eron MD Professor of Medicine University of North Carolina at Chapel Hill - (03/20/13) Revealing the Reservoir, and A Second Cure? - Ronald Swanstrom PhD, UNC Chapel Hill - (03/18/13) CROI Report 2013: Observations on the "Cure Agenda" - By David Margolis MD, UNC Chapel Hill and the Collaboratory of AIDS Researchers for Eradication (CARE) (03/18/13) 20th Conference on Retroviruses and Opportunistic Infections: Eradication/Cure, Prevention, Novel Strategies for administration of PrEP (delivery alternatives) Antiretroviral Therapy/drug resistance/new drugs/Comorbidities - Eric S. Daar, M.D. Chief, Division of HIV Medicine Harbor-UCLA Medical Center Professor of Medicine David Geffen School of Medicine at UCLA - (03/17/13) HIV Prevention at CROI 2013 - Jared Baeten, MD PhD Connie Celum, MD MPH University of Washington - (03/12/13) Inflammation and HIV at CROI 2013: Focus on the Monocyte/Macrophage Axis and Innate Immunity - David H. Shepp, MD Associate Professor of Medicine Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY - (03/11/13) CROI 2013: Cardiovascular Disease and Co-morbidities in HIV - written by David H. Shepp, MD Associate Professor of Medicine, Hofstra North Shore-LIJ School of Medicine North Shore University Hospital - Manhasset, NY (03/11/13) CROI 2013: Comorbidities- Aging/Kidney/Heart/Belly Fat/HCV/Bone/Statins/Frailty - (05/27/13) Neurological, Cognitive Function, Aging/Frailty MACS CMV and HIV Infections Have Opposite Effects on CD8+ T Cell Differentiation and Proliferation - (06/23/13) Phenotypic CD8+ T cell Defects in Treated HIV Infection are Distinct from Those of Aging, Predict Mortality, and May Be Prevented by Earlier ART - (06/23/13) Symptoms of Autonomic Dysfunction in HIV-Infected Patients Receiving Stable ART: "The biggest difference was seen within the male sexual dysfunction domain with 47% of the HIV group experiencing symptoms, compared to 11% of the control group experiencing symptoms" - (05/27/13) Very Early Viral Infection of the Central Nervous System without Evidence of Compartmentalization During Acute HIV-1 Infection - (05/27/13) VLA-4 (Tysabri) Treatment Blocks Virus Traffic to the Gut and Brain Early, and Stabilizes CNS Injury Late in Infection - (05/27/13) A Longitudinal Study of the Effects of Ageing and HIV-1 Infection on Cognitive Performance - (04/02/13) Long-Term Efavirenz Use is Associated with Worse Neurocognitive Functioning - (03/07/13) Long-Term Efavirenz Linked to Worse Neurocognitive Function in US CHARTER Group - written by Mark Mascolini - (03/05/13) Longitudinal Association of HIV-associated neurocognitive disorder (HAND) with Frailty in HIV+ Men - (03/08/13) Older Age and Neurocognitive Function in the Multi-Center AIDS Cohort Study - (03/14/13) Low-Level HIV RNA Declines Over Time in CSF but not in Plasma, "HIV between 2-50 c/ml .....worse cognitive functioning" - (04/01/13) Neuropsychological Performance in Acute HIV - (03/20/13) Similar Cognition Outcomes After 24 Weeks for Tenofovir/FTC + Atazanavir/r (ATV/r)-Experienced HIV+ Subjects or Those Simplifying to Abacavir/3TC+ATV - (03/06/13) Follow-up of HIV-Associated Neurocognitive Disorders in the cART Era: the Neuradapt Study - (04/02/13) Prevalence of Chronic Kidney Disease Among HIV-infected Adults in Care in the United States Medical Monitoring Project, 2009 - (04/01/13) Neuroimaging Correlates of Prior Immunosuppression and Cognitive Status in HIV - (04/10/13) A Randomized, Controlled Trial of a CNS-Targeted Antiretroviral Therapy (ART) Strategy for HIV-Associated Neurocognitive Disorders - (03/29/13) Gold Nanoparticles to Improve Drug Delivery to the Central Nervous System - (04/10/13) Proteinuria is Associated with Neurocognitive Impairment in HIV Infected Subjects Enrolled in the AIDS Clinical Trials Group (ACTG) Longitudinal Cohort Study (ALLRT) - (03/28/13) High Grade Liver Steatosis and Cognitive Impairment in HIV+ patients - (04/09/13) Cognitive Rehabilitation Protocol in HIV/AIDS outpatients with ANI and MND: results and clinical applicability - (04/09/13) Associations Between Regional Fat Deposition and Neurocognitive Function in the Multicenter AIDS Cohort Study - (04/09/13) Detectable HIV DNA is Associated with Reduced Cerebellar and Subcortical Gray Matter Volumes - (04/08/13) Maraviroc Intensification in Virally Suppressed HIV Infected Subjects Leads to Improvement in Neurocognitive Test Performance and Declines in Immune Activation - (04/07/13) Changing CSF Concentrations of Neurofilament Light Chain, Tau and Amyloid Proteins, Characterize Evolving CNS Injury in HIV-1 Infection - (04/01/13) Reduced Region-Specific Corpus Callosum Volumes Correlate with Low Nadir CD4 an Decreased Cognition in HIV-Infected Carriers of the ApoE4 Allele - (04/01/13) Prevention, PrEP, iPrEX, PrEP Fails/Voice-Adherence New HIV Rate High After iPrEx Men Stop Truvada PrEP (or Placebo): when taking Truvada PrEP it works - written by Mark Mascolini - (03/08/13) HIV Prevention Fails in All Three VOICE Arms, as Daily Truvada PrEP Falls - written by Mark Mascolini - (03/04/13) Resistance Transmission Wide US Study Finds 16% With Newly Diagnosed HIV Carry Resistant Virus - written by Mark Mascolini - (03/06/13) New ART Drug Delivery Approaches, Long-Acting ARTs Long-Acting Integrase Inhibitor Shields Macaques From Anal Simian HIV - written by Mark Mascolini - (03/04/13) PrEP GSK744 Integrase Administered Monthly Perhaps Quarterly Prevents HIV-Infection in Monkeys - (03/07/13) A Tenofovir Disoproxil Fumarate Intravaginal Ring Completely Protects Against Repeated SHIV Vaginal Challenge in Nonhuman Primates - (03/11/13) Research Spotlight: Nanomedicines for HIV therapy - (04/10/13) Small Magnetite Antiretroviral (SMART) Nanoparticles for Targeted Drug Delivery to Viral Reservoirs - (04/10/13) Enhanced Pharmacological Properties of Efavirenz Formulated as Solid Drug Nanoparticles.... "Studies to determine whether bioequivalence can be obtained with a lower dose of SDN are now planned in healthy volunteers" - (04/10/13) New Approaches to ART Drug Delivery: long-acting ARTs, nanoparticles - (04/10/13) Gold Nanoparticles to Improve Drug Delivery to the Central Nervous System - (04/10/13) Women, Menopause, Aging, Pregnancy/Viral failure, Kids ART Increased Hot Flash Severity and Burden among Perimenopausal HIV-infected Women - (03/28/13) Trends in and factors associated with virological failure among women conceiving on cART in Western Europe - (03/18/13) European cART Failure Rate During Pregnancy 19% and Falling Fast - written by Mark Mascolini - (03/17/13) One Quarter of US Pregnant Insured Women Not Tested for HIV, Despite CDC Advice - written by Mark Mascolini - (03/17/13) Virologic Failure in 40% of Perinatally Infected US Children--Regimen Switching Slow - written by Mark Mascolini - (03/12/13) Sexual Behavior differs: by gay, heterosexual, bisexual Bisexual HIV+ US Men Differ in Key Ways from HIV+ Heterosexuals and Gays - CDC Study - written by Mark Mascolini - (03/17/13) HIV Care Cascade HIV Care Cascade Analysis Not So Dire in Large US Healthcare System - written by Mark Mascolini - (03/18/13) CD4 Count Matters 200 to 1000 Predicts AIDS Events The Incidence of AIDS Defining Events (ADEs) at a Current CD4 Count > 200/mm3 in the Post Combination Antiretroviral Therapy Era - (03/11/13) Fewer CD4s at HIV Diagnosis Tied to Higher Risk of non-AIDS Deaths - written by Mark Mascolini - (03/11/13) CD4 Count Affects Non-AIDS Risk in People Yet to Start Antiretrovirals - written by Mark Mascolini - (03/07/13) Metabolics, Heart Disease, Frailty, Bone, Mortality (nonAIDS), Aging, statins, Inflammation, Activation HIV is an Independent Predictor of Lower Bone Mineral Density in HIV-positive Subjects Compared to HIV-negative Subjects - (07/24/13) Lower Baseline CD4 is Associated with Greater Loss of Bone Mineral Density after ART Initiation - (05/27/13) Heart Disease/CROI - (03/17/13) Coronary Artery Danger Signals More Common in Young HIV+ Men Than HIV- Men - written by Mark Mascolini - (03/05/13) Age Raises Rate of Dangerous Coronary Artery Plaques in HIV+ But Not HIV- MACS Men - written by Mark Mascolini - (03/05/13) Higher MI, ESRD, Cancer Rates With HIV--But Not Necessarily at Younger Age - written by Mark Mascolini - (03/05/13) Age Raises Rate of Dangerous Coronary Artery Plaques in HIV+ But Not HIV- MACS Men - written by Mark Mascolini - (03/05/13) Frailty and Circulating Markers of Inflammation in HIV+ and HIV- Men in the Multicenter AIDS Cohort Study - (03/07/13) HIV-Infected Adults Are at Greater Risk for Myocardial Infarction (MI), End-stage Renal Disease (ESRD), and Non-AIDS-defining Cancers, But Events Occur at Similar Ages Compared to HIV-uninfected Adults (VA) - (03/11/13) Subclinical Heart Disease is Greater Among HIV+ vs HIV- & Increases with Age in MACS - (03/11/13) Short-Term Mortality After Heart Attack With HIV Fell Over Past Decade in D:A:D - written by Mark Mascolini - (03/11/13) Rise in Heart Disease Risk With Age Slightly Greater With HIV Than in General Population.......[DAD study also shows that reducing risk factors can have a big impact on reducing heart disease] - written by Mark Mascolini - (03/09/13) Proportion of HIV Deaths Due to Heart Disease Almost Doubles in France From 2000 to 2010 - written by Mark Mascolini - (03/11/13) Projecting CVD risks in HIV-infected individuals in the US: competing risks and premature aging - (03/12/13) Cardiovascular-related Deaths in HIV-infected Patients between 2000 and 2010 - The ANRS EN20 Mortalite 2010 Survey - (03/12/13) Soluble CD14 Declines in Virologically Suppressed Women Switching from PI or NNRTI to Raltegravir: The Women, Integrase, and Fat Accumulation Trial - (03/12/13) HIV and Coronary Artery Calcium Score: Comparison of the Hawaii Aging with HIV Cardiovascular Study (HAHC-CVD) and the Multi-Ethnic Study of Atherosclerosis (MESA) - (03/14/13) Human Immunodeficiency Virus Infection and Risk of Venous Thromboembolism - (03/14/13) Non-AIDS Cancer Rate Higher With Longer PI (But Not NNRTI) Therapy in D:A:D - written by Mark Mascolini - (03/14/13) Framingham Score May Underestimate CHD Risk With HIV, HCV, and HIV/HCV - written by Mark Mascolini - (03/12/13) The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/16/13) HIV and HIV/HCV Boost Risk of Venous Thromboembolism in Large Veterans Cohort - written by Mark Mascolini - (03/14/13) Fracture Among Older and Younger HIV+ Medicare Beneficiaries - (03/28/13) Peak Bone Mass Lower in Young HIV+ vs HIV- Men--and Bone Structure Abnormal - written by Mark Mascolini - (03/06/13) Lower Baseline CD4 is Associated with Greater Loss of Bone Mineral Density after ART Initiation - (03/09/13) Noncalcified Coronary Plaque and Macrophage Activation are Increased in HIV-Infected Women - (03/18/13) Cardiovascular-related Deaths in HIV-infected Patients between 2000 and 2010, The ANRS EN20 Mortalite 2010 Survey: the 3rd leading cause of death was liver disease 10.8%, non-AIDS cancers 22.1%, AIDS 25%, CVD deaths/sudden deaths 13.6% - (04/02/13) Weight Gain Inflates Diabetes Risk More in Veterans With Than Without HIV - written by Mark Mascolini - (03/15/13) Continued Declines in AIDS and non-AIDS Related Mortality with Persistently Higher Death Rates among Blacks and the Publicly Insured in the HIV Outpatient Study (HOPS), 1996-2009 - (04/01/13) Statin therapy and mortality in HIV-infected individuals; A Danish nationwide population-based cohort study. - (03/20/13) Every Year of Statin Therapy Boosts Diabetes Risk 10% in US HIV Cohort - written by Mark Mascolini - (03/20/13) Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study - (03/20/13) Is Statin Use Associated with Incident Diabetes Mellitus among Patients in the HIV Outpatient Study (HOPS)? - (03/20/13) Impact of Statin Exposure on Mortality and Non-AIDS Complications in HIV Patients on HAART - (03/19/13) HIV+ Status, Low Income, and Active Hepatitis C Virus Infection are Associated with Shorter Leukocyte Telomere Length in a Cohort of HIV+ and HIV- Adults - (03/28/13) Fall Frequency and Associated Factors among Men and Women with or at Risk for HIV Infection - (04/05/13) High Grade Liver Steatosis and Cognitive Impairment in HIV+ patients - (04/09/13) Associations Between Regional Fat Deposition and Neurocognitive Function in the Multicenter AIDS Cohort Study - (04/09/13) Maraviroc plus Raltegravir dual Therapy in Aviremic HIV infected Patients with Lipodystrophy : Results from the ROCnRAL ANRS 157 Study. - (04/07/13) HIV is an Independent Predictor of Lower Bone Mineral Density in HIV-positive Subjects Compared to HIV-negative Subjects - (04/01/13) Lower Pretreatment CD4s Tied to More Bone Loss After 96 Weeks of ART - written by Mark Mascolini - (03/17/13) 25-hydroxy Vitamin D and Bone Mineral Density (BMD) Increased with Intermittent ART versus Continuous ART in the SMART Body Composition Substudy - (04/01/13) Change in Lean Body Mass and Association with Bone Mineral Density Change in Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202 - (03/28/13) HIV Protease Inhibitors & HIV Recombinant Proteins Induce Senescence & Alter Fate of Human Bone Marrow Mesenchymal Stem Cells - (03/28/13) Cardiac function is altered in Aged Transgenic AIDS Mice in vivo: Insights into Age-related HIV-1 Changes in Patients - (03/28/13) Obesity Affects Almost One Quarter of HIV-Positive US People in Care in CDC Analysis - written by Mark Mascolini - (03/13/13) Inflammation, CVD, Aging, NonAIDS Events, Microbial Translocation Inflammation, Monocyte Activation in CVD & Non-AIDS Events - (03/12/13) Soluble Markers of Inflammation & Coagulation, but not T-Cell Activation, Predict Non-AIDS Defining Events During Suppressive Antiretroviral Therapy (ART) - (03/13/13) The Contribution of Intestinal Epithelial Cell Damage, Microbial Translocation, and HIV Status to an Inflammaging Phenotype - (03/13/13) The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy - (03/19/13) The Effect of Statins on Immune activation and Inflammation in HIV-Infected Subjects on Antiretroviral Therapy: a Randomized Placebo Controlled Trial - (03/19/13) Reservoirs, Cure, Eradication "Functional Cure" of HIV Claimed for Baby Treated 30 Hours After Birth - written by Mark Mascolini - (03/04/13) Impact of Interleukin 7 and Raltegravir plus Maraviroc intensification on total HIV DNA reservoir: Results from ERAMUNE 01 - (04/07/13) HIV Controllers Have Inflammation & ART Should Be "Considered", study investigators say - (04/06/13) End Organ HIV Reservoirs - Integrated HIV DNA and Associated Histiocyte Marker mRNA in Autopsy Samples of Non-lymphoid Tissue Including the CNS - (03/22/13) The Kidney A Potential HIV Reservoir - Bidirectional Passage of HIV Between T cells and Renal Epithelial cells through Virological Synapse Formation - (03/22/13) Hype and the HIV cure (baby/CROI) - (04/01/13) Doctors claim to have cured girl of HIV (baby/CROI) - (04/01/13) Baby Cure at CROI - (03/06/13) Was An Infant Cured Of HIV? - (03/04/13) For First Time, Baby Is Cured of H.I.V., Doctors Say - (03/04/13) Protease Monotherapy, Neurologic Function Protease Inhibitor Monotherapy Is Not Associated with a Higher Rate or a Different Pattern of Neurocognitive Impairment than Triple Drug Therapy - (04/01/13) Renal, Kidney Factors Associated with Tenofovir-related Adverse Events and Drug Exposure in HIV-positive Patients - (04/01/13) Common Conditions - Age, Low BMI, Mild Renal Impairment, Ritonavir Use - Increase Tenofovir Exposure in a Large Unselected Cohort of HIV+ Women - (04/01/13) Reversibility of tenofovir-associated decline in renal function - (03/22/13) Evaluation of Glomerular Function, Renal Blood Flow, and Exposure-Safety Relationship Following Administration of EVG/COBI/FTC/TDF - (03/21/13) Lower Current CD4s--But Not Tenofovir--Predict Advanced CKD/ESRD in D:A:D - written by Mark Mascolini - (03/15/13) Long-Term Changes in Renal Parameters in ART-naïve Subjects Randomized to ABC/3TC or TDF/FTC with ATV/r or EFV: ACTG A5224s, a Sub-study of A5202 - (03/12/13) Lung Morbidity High Prevalence and Severity of Pulmonary Emphysema is Associated with Cardiovascular Morbidity - (03/14/13) Hodgkin Lymphoma Hodgkin Lymphoma Is Almost As Prevalent As Non-Hodgkin Lymphoma in HIV+ Patients With Sustained Viral Suppression And Limited Immune Deficiency - (04/01/13) Smoking Rates High in HIV+ Smoking Rate Twice Higher With Than Without HIV in First National US Study - written by Mark Mascolini - (03/05/13) New HIV Drugs, ARTs, Clinical Studies Safety and Antiviral Activity of MK-1439, a Novel Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), In Treatment-Naïve HIV-Infected Patients - (03/05/13) Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of MK-1439, a Novel HIV Non-Nucleoside Reverse Transcriptase Inhibitor, in Healthy Subjects - (04/04/13) Seven-Day Monotherapy With New NNRTI Yields Sharp Viral Load Drop - written by Mark Mascolini - (03/05/13) Trends in darunavir resistance-associated mutations and phenotypic resistance in commercially tested US clinical samples: 2006 to 2012 - (03/14/13) Resistance to Darunavir Falling Since Approval of the Protease Inhibitor in 2006 - written by Mark Mascolini - (03/11/13) Association Between Early Virologic Response and Immunologic Outcomes in Raltegravir-treated Patients - (03/13/13) NRTI-Sparing Second-Line Regimen Holds Its Own in Randomized Trial - written by Mark Mascolini - (03/06/13) Comparative Study of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate, Each with Elvitegravir, Cobicistat, and Emtricitabine, for HIV Treatment - (03/05/13) Tenofovir Alafenamide Pharmacokinetics in Renal Impairment: Potential for Administration without Dose Adjustment - (03/22/13) New tenofovir prodrug virologically equivalent to TDF--and easier on kidneys and bone - written by Mark Mascolini - (03/05/13) Homology models of the attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action - (03/13/13) CCR5/CCR2 Antagonist Cenicriviroc: 24-Week Data vs Efavirenz in ART-Naive - written by Mark Mascolini - (03/08/13) Week 24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with FTC/TDF, in Treatment-naïve HIV-1 Infected Adults with CCR5-tropic virus - (03/08/13) SECOND-LINE: Ritonavir-Boosted-Lopinavir with 2-3N(t)RTI or Raltegravir in HIV-Positive Subjects Virologically Failing First-Line NNRTI/2N(t)RTI antiretroviral therapy - (03/28/13) Higher CD4 Gains With 2nd-Line Regimen Excluding NRTIs in Randomized Trial - written by Mark Mascolini - (03/07/13) Emergent Drug Resistance from the HIV-1 Phase 3 Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Studies through Week 96 - (03/15/13) Dolutegravir Dolutegravir Treatment Response and Safety by Key Subgroups in Treatment Naive HIV Infected Individuals - (03/16/13) Dolutegravir (DTG) Versus Raltegravir (RAL) in ART-Experienced, Integrase-Naive Subjects: 24-Week Interim Results From SAILING (ING111762) - (03/06/13) Dolutegravir Superior to Raltegravir in ART-Experienced Integrase Inhibitor Naive at 24 Weeks - written by Mark Mascolini - (03/06/13) Distribution and Antiviral Activity in Cerebrospinal Fluid (CSF) of the Integrase Inhibitor, Dolutegravir (DTG): ING116070 Week 16 Results - (03/06/13) SINGLE AND MULTIPLE DOSE DOLUTEGRAVIR PHARMACOKINETICS IN THE GENITAL TRACT AND COLORECTUM OF HIV NEGATIVE MEN AND WOMEN - (04/04/13) Dolutegravir Has No Effect on the Pharmacokinetics of Methadone or Oral Contraceptives With Norgestimate and Ethinyl Estradiol - (04/04/13) HCV, HBV, Liver Disease, Aging HCV at CROI - (03/17/13) Protective Effect of HBV-active c-ART against primary HBV-Infection - (03/05/13) Pharmacokinetic study of raltegravir in HIV-infected patients with end stage liver disease: LIVERAL ANRS 148 study - (04/02/13) Triple Combination Therapy Telaprevir vs Boceprevir, in Spain, Early Results, in Mono- and Coinfected - (03/29/13) Absence of a Significant Pharmacokinetic Interaction Between the HCV Protease Inhibitor Boceprevir and HIV-1 NNRTI Rilpivirine - (03/29/13) Increased Plasma and Intracellular Ribavirin Concentrations Associated With Telaprevir Use - (03/29/13) On-treatment and Sustained Virologic Response Rates of Telaprevir-based HCV Treatments Do Not Differ Between HIV/HCV Co-infected and HCV Mono-infected Patients - (03/29/13) Intra- and Extra-Hepatic Correlates of Plasma Viral Clearance in Patients with Chronic Hepatitis C Genotype 1 Treated with GS-7977 and Ribavirin - (03/29/13) Predictors of Mortality among United States Veterans with Human Immunodeficiency Virus and Hepatitis C Virus (HIV/HCV) Co-Infection - (04/01/13) Hepatitis C Co-infection and the Risk of Chronic Kidney Disease in HIV-infected Individuals: Does Hepatitis C Viremia Matter? - (04/01/13) Impact of Hepatitis Serostatus on Hospitalization Rates and Reasons for Admission in a Multi Center Cohort of Persons Living with HIV in the U.S Multi-Center Cohort of persons Living with HIV in the US - (04/01/13) Does persistent hepatitis C viremia lead to advanced liver fibrosis progression early after acute hepatitis C infection in HIV coinfection? - (04/01/13) Incidence and Progression to Cirrhosis of HCV Superinfection in Persons Living with HIV (PLHIV): accelerated progression risk 'not as dramatic' - (04/01/13) Hepatitis C Co-infection and the Risk of Chronic Kidney Disease in HIV-infected Individuals: Does Hepatitis C Viremia Matter? - (04/01/13) Hepatic Fibrosis and Immune Phenotypes Vary by Hepatitis C Viremia in HIV Infection: A Women's Interagency HIV Study.....[from Jules: HCV Viremia Increased Fibrosis/Immune-Dysregulation; HIV Drives Immune Activation but HCV Contributes to Immune Activation] - (03/15/13) The Effect of Hepatic Fibrosis and HCV viremia on Serum Inflammatory Mediators in HIV Infection - a Women's Interagency HIV Study - (03/15/13) NEW HCV DRUGS, Treating Acute HCV in HIV+ Treatment of Acute HCV in HIV-infected MSM Incorporating Telaprevir - (03/13/13) Telaprevir Combination Treatment in Hard-to-treat African American, Null Responder G1 Chronic Hepatitis C Patients: Early Data From the OUTLOOK Study - (03/09/13) Telaprevir, Peginterferon and Ribavirin Combination Therapy for Chronic HCV Genotype 1 in HCV/HIV Co-infected Patients: Early Response and Viral Resistance - (03/09/13) High Early Virological Response with Telaprevir-PegIFN-RBV in treatment-experienced, HCV genotype 1, HIV coinfected patients: ANRS HC26 TelapreVIH Study - (03/08/13) SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders - (03/06/13) First interim results from a phase IIa study evaluating an all-oral regimen of Simeprevir and Sofosbuvir in prior null responder Hepatitis C patients - press release - (03/04/13) ELECTRON: 100% SVR Rate for Once-Daily Sofosbuvir Plus Ledipasvir Plus Ribavirin Given for 12 Weeks in Treatment-Naïve and Previously Treated Patients With HCV GT 1 - (03/04/13) RISK OF VIROLOGIC RELAPSE IN HEPATITIS C, GENOTYPE 1-INFECTED SUBJECTS AFTER 8, 12, OR 24 WEEKS OF TREATMENT WITH ABT-450/r + ABT-267 + ABT-333 + RBV: IDENTIFYING OPTIMAL TREATMENT DURATION - (03/04/13) 12 WEEKS OF ABT-450/r, NON-NUCLEOSIDE INHIBITOR AND RBV ACHIEVED SVR24 IN >90% OF TREATMENT-NAIVE HCV GT1 PATIENTS AND 47% OF PRIOR NONRESPONDERS - (03/04/13) Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the HCV protease inhibitor faldaprevir in healthy volunteers - (03/04/13) STARTVerso 4: High rates of early virologic response in HCV genotype 1/HIV-co-infected patients treated with faldaprevir plus pegIFN and RBV - (03/04/13) Boerhinger Ingelheim Announes Interim Results Evaluating Virologic Response Rates in HCV/HIV Coinfected Patients Treated with HCV Protease BI201335, and Drug Drug Interaction Studies with HIV ARTs - (03/04/13) Fall Frequency and Associated Factors among Men and Women with or at Risk for HIV Infection - (04/01/13) NEW HIV DRUGS at CROI - (03/19/13) IL-6 Plus D-dimer Predict Non-AIDS Diagnoses and Death in 3-Cohort HIV Group - written by Mark Mascolini - (03/19/13) HIV Care Cascade Analysis Not So Dire in Large US Healthcare System - written by Mark Mascolini - (03/18/13) HIV Protease Inhibitors & HIV Recombinant Proteins Induce Senescence & Alter Fate of Human Bone Marrow Mesenchymal Stem Cells - (03/18/13) HCV at CROI - (03/17/13) Prevalence of CSF Alzheimer's Disease-like profiles in middle-aged HIV+ individuals, relation to APOE genotyping and HIV disease markers - (03/09/13) Tenofovir in Intravaginal Ring Protects 6 of 6 Macaques From SHIV Challenge - written by Mark Mascolini - (03/08/13) ANRS-HC27 BocepreVIH Interim Analysis: High EVR with Boceprevir+peg-IFN+ RBV in HCV/HIV-co-infected Patients with Previous Failure to peg-IFN+RBV - (03/08/13) Simeprevir (TMC435) with peginterferon/ribavirin in patients co-infected with chronic genotype-1 HCV and HIV-1: Week-24 interim analysis of the TMC435-C212 study - (03/07/13) High Efficacy of Sofosbuvir in Combination with Weight Based Ribavirin for 24 weeks in Difficult to Treat HCV Infected Genotype-1 Patients - (03/06/13)